Similarly, PSMA-PET imaging as a reflex test if CTBS findings are negative or equivocal was estimated to result in an expected increase in life expectancy by 854 life-years (95% UI, 683-1015 life-years) or 693 QALYs (95% UI, 561-763 QALYs) and a decrease in prostate cancer mortality by 67 deaths (95% UI, 58-73 deaths) compared with conventional imagining. The gene discussed is FOLH1; the disease is prostate carcinoma.